# US 2026/0028587 A1 · Compositions and methods for microglia replacement therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028587 A1
- Document ID: US20260028587A1
- Status: Published application
- Kind: A1
- Application number: 19/347,649
- Filed: 2025-10-01
- Published: 2026-01-29
- Earliest claimed: 2018-09-10
- Assignees: Savanna Biotherapeutics, Inc.; The Board of Trustees of the Leland Stanford Junior University
- Applicants: Savanna Biotherapeutics, Inc.; The Board of Trustees of the Leland Stanford Junior University
- Inventors: Frederick Christian BENNETT; Peter A. THOMPSON; Mariko L. BENNETT; Andy J. JENNINGS
- Web page: https://patentgrep.com/patent/US20260028587A1

## CPC

- C12N 5/0642: {Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells}
- A61K 40/10: characterised by the cell type used
- A61K 40/414: {Nervous system antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/7153: {for colony-stimulating factors [CSF]}
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1)
- A61K 2239/31: characterized by the route of administration
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/11: from blood or immune system cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods and compositions for microglia replacement therapy in a subject in need thereof. In some cases, the method involves administering myeloid cells to the central nervous system of a subject. In some cases, the myeloid cells are derived from embryonic or extraembryonic tissue. In some cases, the myeloid cells are genetically modified. The genetic modification may include a colony stimulating factor 1 receptor (CSF1R) variant that is resistant to a CSF1R inhibitor, yet retains sensitivity to its ligand (e.g., CSF1, IL34).

## Claims

### Claim 1

A method for microglia cell replacement therapy, wherein the method comprises:
(a) introducing a microglial cell inhibitor into a central nervous system (CNS) of a subject in need thereof, thereby inactivating, suppressing, or depleting a native microglial cell population of the subject in need thereof; and
(b) introducing a composition into the CNS of the subject in need thereof,
wherein the composition comprises a myeloid cell:
(i) comprising a receptor tyrosine kinase that comprises a mutation that reduces the sensitivity of the receptor tyrosine kinase to the microglial cell inhibitor, and
(ii) has the potential to differentiate into a microglia-like cell, and
wherein the myeloid cell replaces the native microglial cell population by differentiating into a microglia-like cell in vivo.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mutation is an amino acid substitution, deletion, or insertion.

### Claim 3 (depends on 2)

The method of claim 2, wherein the amino acid substitution, deletion, or insertion is within the JM-domain, the N(P)-loop, the A-loop, the C-loop, the KID region, or the Hinge region of the receptor tyrosine kinase.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amino acid substitution, deletion, or insertion is at an amino acid residue corresponding to an amino acid at position 647, 550, 669, 663, 795, 637, 796, 666, or 546 of SEQ ID NO: 3.

### Claim 5 (depends on 4)

The method of claim 4, wherein the amino acid substitution comprises:
(a) a tyrosine-to-phenylalanine substitution at an amino acid residue corresponding to an amino acid at position 546 (Y546F) of SEQ ID NO: 3,
(b) a threonine-to-isoleucine substitution at an amino acid residue corresponding to an amino acid at position 663 (T663I) of SEQ ID NO: 3,
(c) a glycine-to-alanine substitution at an amino acid residue corresponding to an amino acid at position 795 (G795A) of SEQ ID NO: 3,
(d) an aspartate-to-alanine substitution at an amino acid residue corresponding to an amino acid at position 796 (D796A) of SEQ ID NO: 3,
(e) a valine-to-isoleucine substitution at an amino acid residue corresponding to an amino acid at position 647 (V647I) of SEQ ID NO: 3,
(f) a tryptophan-to-phenylalanine substitution at an amino acid residue corresponding to an amino acid at position 550 (W550F) of SEQ ID NO: 3,
(g) a tryptophan-to-leucine substitution at an amino acid residue corresponding to an amino acid at position 550 (W550L) of SEQ ID NO: 3,
(h) a glycine-to-alanine substitution at an amino acid residue corresponding to an amino acid at position 669 (G669A) of SEQ ID NO: 3,
(i) a glycine-to-valine substitution at an amino acid residue corresponding to an amino acid at position 669 (G669V) of SEQ ID NO: 3,
(j) a methionine-to-leucine substitution at an amino acid residue corresponding to an amino acid at position 637 (M637L) of SEQ ID NO: 3, or
(k) a cysteine-to-alanine substitution at an amino acid residue corresponding to an amino acid at position 666 (C666A) of SEQ ID NO: 3.

### Claim 6 (depends on 4)

The method of claim 4, wherein the myeloid cell further comprises a nucleic acid sequence encoding the receptor tyrosine kinase, and wherein the receptor tyrosine kinase has at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 3.

### Claim 7 (depends on 6)

The method of claim 6, wherein the nucleic acid sequence encodes a receptor tyrosine kinase comprising an amino acid sequence as set forth in SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.

### Claim 8 (depends on 1)

The method of claim 1, wherein the microglial cell inhibitor inhibits tyrosine kinase activity of the receptor tyrosine kinase.

### Claim 9 (depends on 1)

The method of claim 1, wherein the microglial cell inhibitor is selected from the group consisting of: pexidartinib (PLX-3397), PLX-7486, PLX-5622, ARRY-382, BLZ945, DCC-3014, AMG-820, GW-2580, linifanib (ABT-869), OSI-930, and combinations thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the myeloid cell is a myeloid precursor cell, a myeloid progenitor cell, an erythromyeloid precursor cell, an erythromyeloid progenitor cell, a non-hematopoietic stem cell (HSC)-derived myeloid cell, a hematopoietic stem cell (HSC)-derived myeloid cell, a hematopoietic progenitor cell, a non-HSC-derived myeloid cell, or a yolk-sac-derived myeloid cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein the myeloid cell is derived from a hematopoietic stem cell or a hematopoietic progenitor cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein the myeloid cell is derived from a stem cell, an embryonic stem cell, a pluripotent stem cell, or an induced pluripotent stem cell (iPSC).

### Claim 13 (depends on 1)

The method of claim 1, wherein the myeloid cell is a human myeloid cell.

### Claim 14 (depends on 1)

The method of claim 1, wherein the introducing the myeloid cell comprises transplanting the myeloid cell from an individual that is healthy or an individual that does not have a peripheral blood disorder or blood cancer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the introducing the myeloid cell comprises transplanting a myeloid cell from an individual that is afflicted with a neurological disease or disorder.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurological disease or disorder comprises a leukodystrophy or a neuroinflammatory disease.

### Claim 17 (depends on 16)

The method of claim 16, wherein the leukodystrophy comprises any one or more of: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), Globoid cell leukodystrophy (Krabbe disease), Metachromatic leukodystrophy, Mucopolysaccharidosis IIIA/B (Sanfilippo syndrome), Mucopolysaccharidosis IIA (Hunter syndrome), Gaucher disease Type 11/111, Niemann-Pick C1, Cerebrotendinous xanthomatosis (CTX), Canavan disease, and Alexander disease.

### Claim 18 (depends on 16)

The method of claim 16, wherein the neuroinflammatory diseases comprises any one or more of: Multiple sclerosis, Neuromyelitis optica, Optic neuritis, or Transverse myelitis, Progressive supranuclear palsy, Corticobasal degeneration, Dementia with Lewy Bodies, Multiple System Atrophy, Alzheimer's disease, Frontotemporal dementia (FTD), Parkinson's disease Huntington's disease, and Rett syndrome.

### Claim 19 (depends on 1)

The method of claim 1, wherein the introducing the myeloid cell in the subject further comprises obtaining a myeloid cell, a somatic cell, or a stem cell from the subject or an allogeneic donor source.

### Claim 20 (depends on 1)

The method of claim 1, wherein the tyrosine receptor kinase possesses normal ligand-dependent signaling or ligand-independent signaling in the presence or absence of the microglial cell inhibitor.

### Claim 21 (depends on 1)

The method of claim 1, wherein the microglia-like cell repopulates in a brain region of the subject such that greater than about 5% of the number of microglial cells in the brain region of the subject are the microglia-like cell differentiated from the myeloid cell.

### Claim 22 (depends on 1)

The method of claim 1, wherein the microglia-like cell engrafts into a parenchyma of the brain of the subject.

### Claim 23 (depends on 1)

The method of claim 1, wherein the microglia-like cell expresses, in addition to the receptor tyrosine kinase:
(a) TMEM119, P2RY12, or TREM2; and
(b) a human-specific cell marker.

### Claim 24 (depends on 1)

The method of claim 1, wherein the receptor tyrosine kinase is a Colony Stimulating Factor-1 Receptor (CSF1R) protein.

### Claim 25 (depends on 1)

The method of claim 1, wherein the receptor tyrosine kinase comprises a mutation at one or more amino acid residues selected from the group consisting of: V647, W550, G669, T663, G795, M637, D796, C666, Y546, or any combination thereof.

### Claim 26 (depends on 2)

The method of claim 2, wherein the receptor tyrosine kinase comprises one or more amino acid substitutions selected from the group consisting of: V647I, W550F, W550L, G669A, G669V, T663I, G795A, M637L, D796A, C666A, and Y546F.
